Translational Oncology Training Program

摘要 癌症是美国的第二大死因，在发现新的和 更有效的方法来治愈这种毁灭性的疾病，这需要做出巨大的努力来翻译基本的 把科学知识带入临床。为了实现这一目标并进一步促进转化型癌症研究， 当务之急是建立一个可持续的计划，以培养和教育下一代科学家和 临床医生，他们必须有广泛的知识，并有能力与同事沟通和工作 菲尔兹。翻译肿瘤学培训计划(TOTP)的目标是确保下一个 新一代癌症研究人员配备了工具和知识，使他们能够 将台面上的发现带入临床试验，反之亦然。参加该项目的研究员和学生 将接受四个不同但高度整合的主题的独特培训：临床前建模(PCM)；癌症 影像引导(CIG)；癌症生物验证(CBV)；临床翻译(CLT)。PCM专注于分析 使用不同的临床前模型对参与肿瘤进展的途径和信号进行研究，以确定 潜在的治疗靶点和生物标志物。CIG提供最先进的图像引导诊断培训 方法和基于纳米技术的药物输送系统。CBV的实习生将学习最新信息 具备多组学环境下的生物信息学技能，以便研究和分析大型队列患者数据库。 CLT的教授在临床试验中有丰富的经验，他们为如何翻译提供指导 将基础知识转化为临床试验。学员将在第一年轮换四个主题中的三个 同时接受所有四个主题的说教讲座。他们还将组建一个由两人组成的指导团队 博士和医学博士教职员工。这个T32项目的大部分导师都在血液学/肿瘤学和 癌症生物系。这一结构融合了Wake中强大的临床和基础科学实体 森林浸会综合癌症中心(WFBCCC)。然而，这一培训计划是多学科的 总的来说，教官来自11个不同的部门。该计划是独一无二的，有许多创新的培训 工具：(I)高度整合的4个翻译主题，包括授课和动手轮换 在主题中；(2)包括博士后和医学博士研究员，以促进坐到床边和 从床边到工作台的癌症转化研究；(Iii)由两位博士组成的个性化导师团队 和医学博士教员；(4)为学员准备临床试验的新兵训练营；(5)面向疾病的支助 来自WFBCCC的团队(DOT)；(Vi)过渡到独立(TTI)计划，以支持学员成为 通过准备K型应用程序实现独立；以及(Vii)广泛的职业机会和 研究生的博士/工商管理硕士等发展计划。因此，通过这个培训项目，博士 研究员/学生将学习如何将基本的科学知识带入床边，而MD研究员将有 对翻译、假设驱动的研究有更深的理解。

Summary Cancer is the second leading cause of death in the US, and many challenges still remain to discover novel and more effective approaches to cure this devastating disease, which requires strong effort in translating basic science knowledge into clinics. To accomplish this goal and further promote translational cancer research, it is imperative to establish a sustainable program to train and educate the next generation of scientists and clinicians, who must have broad knowledge and the ability to communicate and work with colleagues in both fields. The goal of the Translational Oncology Training program (TOTP) is to ensure that the next generation of cancer researchers are equipped with the tools and knowledge that will enable them to bring bench-top discoveries into clinical trials and vice versa. The fellows and students in this program will receive unique training in four different but highly integrated themes: Preclinical Modeling (PCM); Cancer Image Guidance (CIG); Cancer Bio-Validation (CBV); and Clinical Translation (CLT). PCM focuses on analysis of pathways and signaling involved in tumor progression using various preclinical models in order to identify potential therapeutic targets and biomarkers. CIG provides training in state of the art image-guided diagnostic approaches and nanotechnology-based drug delivery systems. Trainees in CBV will learn up-to-date bioinformatics skills in multi-omics setting in order to study and analyze large cohort patient database. Preceptors in CLT have ample experiences in clinical trials and they provide guidance on how to translate basic knowledge into clinical trials. Trainees will rotate through three out of four themes during the first year while taking didactic lectures from all four themes. They will also assemble a mentoring team consisting of both Ph.D and MD faculty. The majority of preceptors of this T32 program are in the Hematology/Oncology and Cancer Biology departments. This structure merges strong clinical and basic science entities in the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC). However, this training program is multidisciplinary and in all, preceptors come from 11 different departments. The program is unique with many innovative training tools: (i) highly integrated 4 translational themes that include both didactic lectures and hands-on rotations among the themes; (ii) inclusion of both Ph.D postdocs and MD fellows to promote both bench-to-bedside and bedside-to-benchtop translational cancer research; (iii) an individualized mentor team consisting of both Ph.D and MD faculty; (iv) boot camp for clinical trial preparation for trainees (v) support from Disease Oriented Teams (DOTs) from WFBCCC; (vi) Transition to Independence (TTI) program to support trainees to become independent through preparation for K-type applications; and (vii) Broad-base career opportunities and development plans such as Ph.D/MBA for graduate students. Therefore, through this training program, Ph.D fellows/students will learn how they can bring basic science knowledge into bedside, while MD fellows will have a deeper understanding of translational, hypothesis-driven research.